Advertisement

 

 

Immunotherapy for Merkel cell carcinoma: a turning point in patient care.

Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
Author Information (click to view)

Chan IS, Bhatia S, Kaufman HL, Lipson EJ,


Chan IS, Bhatia S, Kaufman HL, Lipson EJ, (click to view)

Chan IS, Bhatia S, Kaufman HL, Lipson EJ,

Advertisement

Journal for immunotherapy of cancer 2018 03 236(1) 23 doi 10.1186/s40425-018-0335-9

Abstract

Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.

Submit a Comment

Your email address will not be published. Required fields are marked *

10 − 8 =

[ HIDE/SHOW ]